New eye implant clinical trial recruiting in 2026

In a first, eye prosthesis has restored sight to macular generation patients

In a clinical trial, 27 of 32 participants with advanced macular degeneration regained enough vision to read books, food labels, and subway signs about a year after receiving a prosthetic retina device. This is the first device to restore functional vision to patients with incurable vision loss, though in this case they can only see in black and white, with no shades in between.

There are more than 1,400 listed clinical trials for macular degeneration

The US database of clinical trials listed more than 1,400 macular degeneration trials in early 2026. That doesn't mean every trial is recruiting, but it does indicate there is significant interest in this medical condition.

Using brain implants to restore vision

Several companies are attempting to create brain-computer interfaces that skip over retinas and optic nerves to allow visual input to go straight to the brain, potentially restoring some sight to the blind. Clinical trial findings suggest restored sight is sparse and manifests differently than a sighted person might expect, appearing as specks of "light" clusters called phosphenes to help differentiate one's surroundings.

Scientists using gene therapy recently managed to regenerate retinal cells in the lab—a breakthrough for mammals that could potentially lead to future treatments for human retinal diseases.

A clinical trial is underway in 2026 to help kidney transplant recipients avoid a lifetime of immunosuppressing drugs

This later-stage clinical trial, in Chicago and Taiwan, evaluates the efficacy and safety of a new cellular therapy that may be swapped in for immunosuppressing drugs among kidney transplant recipients. The study randomizes people to either receive standard immunosuppressants or this cellular therapy and fewer immunosuppressants. It only includes kidney transplant recipients receiving organs from live donors so transplant surgery timing won't hinge on the unpredictable schedule of performing surgery and follow-up care when a donor dies.

Restoring vision in impaired patients via CRISPR

Since CRISPR was revealed as a gene editing tool in 2012, it has been on an accelerated track to real-world applications. Among other clinical demonstrations, doctors have now injected a CRISPR treatment directly into eye cells, helping vision-impaired patients see shapes and colors again.

Photodynamic therapy is one current treatment for age-related macular degeneration.

US macular degeneration burden is based on statistical modeling and Medicare claims

Prevalence estimates for age-related macular degeneration in the US are usually based on the Vision and Eye Health Surveillance System. Disease numbers are generated using Bayesian meta-regression (a type of statistical modeling), which pulls together information from multiple sources, including Medicare claims.

Stem cell therapy has shown promise in treating spinal injuries in an early-stage clinical trial.

The origin of LASIK eye surgery, from a lab incident to federal funding and widespread use

After a University of Michigan engineering student suffered retinal burns from an ultrashort pulse laser, researchers realized it could be used to reshape the cornea and improve a person's vision with greater precision than a scalpel and earlier laser technologies. Agencies, including the National Science Foundation, the National Institutes of Health, and the Department of Energy, provided funding to develop and commercialize the procedure.

Why surgeons implant teeth into eyes

What if the thing that restored your vision… was your own tooth? That’s exactly what happened to Brent Chapman. After 20 years without sight, a bizarre surgery using his tooth as a lens restored his vision.

Targeting cholesterol metabolism may help address macular degeneration.

Brain implants are restoring movement and communication in early human trials

Several companies developing brain-computer interfaces have begun testing on humans with promising results. These implants have helped reanimate paralyzed limbs and enable communication, though ethical concerns remain about data privacy.

The US FDA considered mitochondrial replacement therapy during 2014 hearings

An agency committee assessed if this approach could have undesirable ripple effects across multiple generations and whether a clinical trial involving this approach would be appropriate. As of 2026, the US has continued to prohibit this procedure though it is legal in other settings including the UK and Australia.

Dozens of US research projects focus on the zebrafish's ability to grow new retina cells

The small, striped minnow can repair its optic nerve in just under a week. Scientists are interested in hacking its regenerative capacity to grow new retina cells to treat human eye disorders, including macular degeneration. In 2020, the US National Eye Institute had nearly 80 projects focused on zebrafish.

As of February 2025, there are more than 150 clinical trials using CRISPR technology

The clinical trials are designed to determine whether experimental CRISPR-related therapies are safe and effective. The majority of trials involve treatments for blood disorders, including beta thalassemia.

736,900 cochlear implants had been implanted by 2020 worldwide

In the United States, roughly 118,100 devices had been implanted in adults by that point and 65,000 in children. These estimated figures come from the US Food and Drug Administration, which first approved cochlear implants for adults experiencing hearing loss in the mid-1980s, and collected reports from cochlear implant manufacturers approved for the US market.

A planned clinical trial to treat a rare lysosomal storage disorder in utero has buoyed hopes of providing prenatal gene therapies, but it was still awaiting FDA approval to begin enrolling patients as of May 2026.

‘Hope for Healing’: The first-ever use of an in utero stem cell treatment

In 2023, researchers at UC Davis performed the first-ever fetal stem cell transplant, attempting to cure a case of spinal bifida prior to childbirth using stem cells derived from the placenta. The trial, and others including an effort to treat muscular dystrophy, highlight the potential power of stem cell therapy.

Medical professionals have experimented with using mixed reality headsets

Devices like the Apple Vision Pro have helped doctors develop surgical plans for hip and knee replacements using software that provides 3D models and other tools. Virtual screens displayed by mixed reality devices can provide information related to surgical progress, a patient's vitals, and more.

World health experts expect more than 240 million global cases of AMD in 2030

The World Health Organization estimated in 2019 that by 2020 there would be roughly 195.6 million cases of age-related macular degeneration and projected that the number would continue to grow. (Some users may experience a paywall.)

An experimental bionic knee has been directly integrated into the user's muscle and bone—not an external socket—marking a significant prosthetic advancement.

Stem cell therapies

Stem cells' special attributes interest researchers developing new therapeutic tools for a variety of health problems. Much of this research is done with support from the National Institutes of Health (NIH). This page offers a snapshot of research programs funded by the NIH and the health problems those programs focus on.

Wet macular degeneration affects 10%-15% of those with macular degeneration

This form of molecular degeneration refers to when excess blood vessels form in the back of the eye and damage the macula. If someone with this condition looks at straight lines, they will typically appear wavy or crooked.

Vitamins can slow macular degeneration

Research published in 2022 affirmed that vitamin formulations containing vitamins C and E, copper, zinc, lutein, and zeaxanthin—but no beta carotene—can enhance eye health and slow the progression of macular degeneration.

In 2023, the FDA approved gene therapy for sickle cell disease, enabling one-time infusion bespoke treatments that use a patient's own stem cells to effectively cure a painful condition that disproportionately affects people of African American descent.

Watch patient stories describing life with macular degeneration

This video series features patients discussing their experiences with the disorder, family members describing caregiving, and other insights about the disease.

A first-of-its-kind clinical trial taps livers from gene-edited pigs to clean blood

The experimental dialysis-like treatment from United Therapeutics, eGenesis, and OrganOx, is designed to help people with liver failure. The therapy, which involves attaching the modified pig liver externally, filters a patient’s blood so their own livers can temporarily rest and perhaps heal.

As deposits build up under the eye, the retina bends with macular degeneration

The retina bends due to the accumulation of proteins and other materials beneath it. That's considered the milder "dry" form of macular degeneration. Another form, called "wet" macular degeneration, is caused by abnormal blood vessels leaking fluid into the eye, which can rapidly affect central vision.

See how cataracts—a leading cause of vision loss globally—form and how sound waves are often used to help remove them.

The first CRISPR-approved treatment was for sickle cell anemia in 2023

Victoria Gray was the first patient to receive a CRISPR-based therapy, which eliminated her symptoms and restored her health. The therapy's initial cost of $2.2M has kept it out of reach of many patients.

What conditions can be treated with stem cells?

Stem cell research is a global enterprise, and much of the work is being done in Europe. This page gives readers a good sense of the medical conditions stem cell researchers in Europe focus on, and the specific research challenges they address. This page also offers links to in-depth information about many of the research projects.

Open brain surgery is not required for BCIs inserted via blood vessel injection

Synchron's brain-computer interface, the Synchron Switch, takes advantage of preexisting medical devices, such as stents and catheters. Cells grow over the device over a 90-day period, incorporating it into the vessel wall and minimizing clots.

Brain-reading devices are helping paralyzed people to touch

In clinical trials, implanted brain-computer interfaces are allowing dozens of individuals with paralysis to control prosthetics that are restoring a range of skills, including drinking coffee and feeding oneself. One area of related prosthetic research is creating a synthetic sense of touch—coupling the brain implant with pressure sensors in prosthetic robotic fingertips to enable an approximation of a sense of touch.

Early research suggests CAR-T therapy might treat scleroderma, reducing skin thickening

Clinical data from a couple patients in 2025 indicated that one experimental CAR-T therapy called rese-cel was able to genetically reprogram T cells to eliminate certain problematic immune B cells that were causing the condition. The therapy reduced skin thickening and allowed the patients to halt using immunosuppressive medications and steroids.

Late-stage clinical trials indicate that a common arthritis drug may be a promising treatment for a leading cause of hair loss.

Age-related macular degeneration is the primary cause of blindness in older Americans.

Chinese scientists transplanted a pig lung into a human being in 2025—but it had to be removed.

The world's first commercial biological computer combines neurons with silicon

Australian start-up Cortical Labs unveiled CL1, a hybrid chip designed to help scientists study brain function in real-time. The 800,000 lab-grown neurons on the chip are kept viable for six months via a built-in life support system.

In 2026, the FDA proposed a novel approach to expedite reviews of gene therapies for patients with rare genetic disorders such as cystic fibrosis, potentially bypassing the need for years-long clinical trials if approved.

A new daily MS pill is seeking regulatory approval in 2026

In clinical trials, Roche's fenebrutinib showed promise treating primary progressive MS and doubling relapse-free time in patients with relapsing MS as compared to existing treatment. But some liver damage and two possible drug-related deaths in the trials may make it difficult for the drug to net approval. (Some users may encounter a paywall.)

In vitro gametogenesis: using induced stem cells to fertilize eggs

Using stem cells from skin and mouth cells could save hopeful parents time and money and spare egg donors from significant amounts of discomfort throughout the process. There are potential consequences, not just for infertility treatment, but for the ability to create customized cells of any type.

Predictive brain implants raise ethical concerns about patient autonomy after surgery

These devices can accurately forecast neurological events like seizures and suggest or even automatically deliver responses. Their constant monitoring and prescriptive functions may blur the line between patient choice and device influence.

The macula is a small area in the center of the retina

This part of the eye—roughly the bullseye of the back of the eye—is responsible for processing the central vision of the eye. Degradation of the macula, formally called macular degeneration, leads to symptoms including blurred vision, the need for brighter lighting, and difficulty recognizing faces. The condition doesn't affect peripheral vision, but if you lose central vision, you can still be considered blind.

Medical imaging allows 3D printers to create patient-matched devices

With imaging data on a person's anatomy, external prostheses and implants, such as cranial plates or hip joints, can be custom-printed to better match a patient's body. Fabrication of porous structures can promote bone growth, leading to longer-lasting implants.

It's been about 30 years since a new hair loss drug was approved in the US, and women currently have no approved pills for hair loss.

An essay exploring how living day-to-day with a brain implant helps restore a sense of identity

Companies like Neuralink are experimenting with volunteers who have lost control over their bodies. Many of the program's participants claim the most significant benefit from the tool is the ability to perform simple, mundane tasks, such as playing video games or shaking hands, rather than more obvious milestones like walking or eating. This essay explores what it's like, day to day, to use a brain implant.

Read why one man agreed to get a pig kidney in 2025 to replace his own failing organ

The 68-year-old New Hampshire man told USA Today that a motivator for the experimental surgery was his belief that he was going to die anyway, and other people suffering from kidney disease could gain valuable insights. Yet the surgery bought him time—he lived 271 days with a pig organ and later received a human kidney transplant. Clinical trials began in 2026 to test the pig xenotransplants in more people.

A scientist successfully treated her own breast cancer by injecting the tumor with lab-grown viruses.

Drusen are bumps under the retina that distort the vision of most macular degeneration patients

These yellow deposits are made up of proteins and lipids and come in a variety of sizes. They're common in people aged 50 and older, but amassing many of them is often a symptom of age-related macular degeneration—the most prevalent type of macular degeneration.